Burkitt's lymphoma diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 3: Line 3:
{{CMG}}; {{AE}}
{{CMG}}; {{AE}}
== Overview ==
== Overview ==
 
In Burkitts lymphoma tissue biopsy remains the preferred diagnostic study of choice. The biopsy will yield confirmatory results when histpathological and immunohistochemical techniques are used.
== Diagnostic Study of Choice ==
== Diagnostic Study of Choice ==
Biopsy of the affected lymph nodes remains to be the diagnostic study of choice which confirms Burkitts lymphoma.
Biopsy of the affected lymph nodes remains to be the diagnostic study of choice which confirms Burkitts lymphoma.

Revision as of 18:38, 9 January 2019

Burkitt's lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Burkitt's lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study Of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray Findings

CT

MRI

Biopsy

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Burkitt's lymphoma diagnostic study of choice On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Burkitt's lymphoma diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Burkitt's lymphoma diagnostic study of choice

CDC on Burkitt's lymphoma diagnostic study of choice

Burkitt's lymphoma diagnostic study of choice in the news

Blogs on Burkitt's lymphoma diagnostic study of choice

Directions to Hospitals Treating Burkitt's lymphoma

Risk calculators and risk factors for Burkitt's lymphoma diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

In Burkitts lymphoma tissue biopsy remains the preferred diagnostic study of choice. The biopsy will yield confirmatory results when histpathological and immunohistochemical techniques are used.

Diagnostic Study of Choice

Biopsy of the affected lymph nodes remains to be the diagnostic study of choice which confirms Burkitts lymphoma.

Study of choice

  • Lymph node or extra nodal tissue biopsy is diagnostic of Burkitt's lymphoma.
  • To view the characteristic findings of Burkitt's lymphoma biopsy please click here.

Staging

According to the Murphy staging system, there are four stages of Burkitt's lymphoma based on the number of nodes involved and the extra nodal spread.

Staging for Burkitt's lymphoma is provided in the following table:[1]

Murphy staging system
Stage Features
Stage I
  • Single nodal or extra nodal site involvement excluding mediastinum or abdomen[2]
Stage II
  • Single extra nodal tumor with regional nodal involvement
  • Two extra nodal tumors on one side of diaphragm[2]
  • Primary gastrointestinal tumor with or without associated mesenteric nodes
  • Two or more nodal areas on one side of diaphragm
Stage IIR
  • Completely resected intra-abdominal disease
Stage III
  • Two single extra nodal tumors on opposite sides of diaphragm [2]
  • All primary intra thoracic tumors
  • All paraspinal or epidural tumors
  • All extensive primary intra-abdominal disease
  • Two or more nodal areas on opposite sides of diaphragm
Stage IIIA
  • Localized, non-resectable abdominal disease
Stage IIIB
  • Widespread multi organ abdominal disease
Stage IV
  • Initial CNS or bone marrow involvement (< 25%)
Diagnostic results

The following finding(s) on performing biopsy and FISH are confirmatory for Burkitts lymphoma :

  • C-MYC (FISH)[3]
  • Starry-sky pattern (histopathological specimen)[4]

References

  1. Perkins AS, Friedberg JW (2008). "Burkitt lymphoma in adults". Hematology Am Soc Hematol Educ Program: 341–8. doi:10.1182/asheducation-2008.1.341. PMID 19074108.
  2. 2.0 2.1 2.2 Sandlund JT (2012). "Burkitt lymphoma: staging and response evaluation". Br J Haematol. 156 (6): 761–5. doi:10.1111/j.1365-2141.2012.09026.x. PMC 3292702. PMID 22296338.
  3. Aquino G, Marra L, Cantile M, De Chiara A, Liguori G, Curcio MP; et al. (2013). "MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas". Infect Agent Cancer. 8 (1): 37. doi:10.1186/1750-9378-8-37. PMC 3850004. PMID 24079473.
  4. Andrade-Filho Jde S (2014). "Analogies in medicine: starry-sky appearance". Rev Inst Med Trop Sao Paulo. 56 (6): 541–2. PMC 4296877. PMID 25351551.

Template:WH Template:WS